CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer
Haineng Xu(Shanghai Jiao Tong University), Fiona Simpkins(University of Pennsylvania Health System)
Cited by 11
Related Papers
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in <i>BRCA</i> -Mutant Ovarian Cancer Models
|Clinical Cancer Research|2016|292
The Traditional Chinese Medicine Baicalein Potently Inhibits Gastric Cancer Cells
|Journal of Cancer|2016|115
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers
|JCI Insight|2017|71